Kistler-Tiffany Companies’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Kistler-Tiffany Companies’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$33	Hold	100	–	–	﹤0.01%	894
2023 Q1	$43	Hold	100	–	–	﹤0.01%	789
2022 Q4	$53	Hold	100	–	–	﹤0.01%	802
2022 Q3	$0	Hold	100	–	–	﹤0.01%	833
2022 Q2	$0	Hold	100	–	–	﹤0.01%	805
2022 Q1	$0	Hold	100	–	–	﹤0.01%	783
2021 Q4	$0	Hold	100	–	–	﹤0.01%	770
2021 Q3	$0	Hold	100	–	–	﹤0.01%	761
2021 Q2	$1K	Hold	100	–	–	﹤0.01%	722
2021 Q1	$0	Hold	100	–	–	﹤0.01%	699
2020 Q4	$0	Hold	100	–	–	﹤0.01%	691
2020 Q3	$0	Hold	100	–	–	﹤0.01%	654
2020 Q2	$0	Hold	100	–	–	﹤0.01%	640
2020 Q1	$1K	Hold	100	–	–	﹤0.01%	559
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	565
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	580
2019 Q2	$1K	Hold	100	–	–	﹤0.01%	569
2019 Q1	$1K	Hold	100	–	–	﹤0.01%	562
2018 Q4	$0	Hold	100	–	–	﹤0.01%	578
2018 Q3	$1K	Hold	100	–	–	﹤0.01%	550
2018 Q2	$1K	Hold	100	–	–	﹤0.01%	558
2018 Q1	$1K	Hold	100	–	–	﹤0.01%	548
2017 Q4	$1K	Hold	100	–	–	﹤0.01%	545
2017 Q3	$1K	Hold	100	–	–	﹤0.01%	537
2017 Q2	$2K	Hold	100	–	–	﹤0.01%	474
2017 Q1	$2K	Buy	+100	New	+$1.99K	﹤0.01%	482

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BWP

Bernardo Wealth Planning Harleysville, Pennsylvania $585M AUM 17.72% 1-Year Est. Return

Kistler-Tiffany Companies's ZYNE Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q2 2023 at 100 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #894.

Kistler-Tiffany Companies first reported a position in ZYNE in Q1 2017 and has held it in 26 quarters since. The position peaked at $2K in Q2 2017. 41 funds tracked by Wall St. Rank hold ZYNE as of Q2 2023.

Kistler-Tiffany Companies held 100 shares of Zynerba Pharmaceuticals, Inc worth $33 as of Q2 2023.
Kistler-Tiffany Companies left its Zynerba Pharmaceuticals, Inc share count unchanged in Q2 2023.
Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #894 holding.
Kistler-Tiffany Companies first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and has held it in 26 quarters since.
Kistler-Tiffany Companies's Zynerba Pharmaceuticals, Inc position peaked at $2K in Q2 2017.
41 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.